These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 15047179)

  • 21. Role of basic residues within or near the predicted transmembrane helix 2 of the human breast cancer resistance protein in drug transport.
    Cai X; Bikadi Z; Ni Z; Lee EW; Wang H; Rosenberg MF; Mao Q
    J Pharmacol Exp Ther; 2010 Jun; 333(3):670-81. PubMed ID: 20203106
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells.
    Robey RW; Medina-Pérez WY; Nishiyama K; Lahusen T; Miyake K; Litman T; Senderowicz AM; Ross DD; Bates SE
    Clin Cancer Res; 2001 Jan; 7(1):145-52. PubMed ID: 11205902
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interaction of hesperetin glucuronide conjugates with human BCRP, MRP2 and MRP3 as detected in membrane vesicles of overexpressing baculovirus-infected Sf9 cells.
    Brand W; Oosterhuis B; Krajcsi P; Barron D; Dionisi F; van Bladeren PJ; Rietjens IM; Williamson G
    Biopharm Drug Dispos; 2011 Dec; 32(9):530-5. PubMed ID: 22083890
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phytoestrogens/flavonoids reverse breast cancer resistance protein/ABCG2-mediated multidrug resistance.
    Imai Y; Tsukahara S; Asada S; Sugimoto Y
    Cancer Res; 2004 Jun; 64(12):4346-52. PubMed ID: 15205350
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cyclosporin A is a broad-spectrum multidrug resistance modulator.
    Qadir M; O'Loughlin KL; Fricke SM; Williamson NA; Greco WR; Minderman H; Baer MR
    Clin Cancer Res; 2005 Mar; 11(6):2320-6. PubMed ID: 15788683
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ABCG2/BCRP interaction with the sea grass Thalassia testudinum.
    Miguel V; Otero JA; Barrera B; Rodeiro I; Prieto JG; Merino G; Álvarez AI
    Drug Metab Pers Ther; 2015 Dec; 30(4):251-6. PubMed ID: 26444365
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance.
    Nakamura Y; Oka M; Soda H; Shiozawa K; Yoshikawa M; Itoh A; Ikegami Y; Tsurutani J; Nakatomi K; Kitazaki T; Doi S; Yoshida H; Kohno S
    Cancer Res; 2005 Feb; 65(4):1541-6. PubMed ID: 15735043
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lack of interactions between breast cancer resistance protein (bcrp/abcg2) and selected antiepileptic agents.
    Cerveny L; Pavek P; Malakova J; Staud F; Fendrich Z
    Epilepsia; 2006 Mar; 47(3):461-8. PubMed ID: 16529607
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Structure-activity relationships of flavonoids as inhibitors of breast cancer resistance protein (BCRP).
    Pick A; Müller H; Mayer R; Haenisch B; Pajeva IK; Weigt M; Bönisch H; Müller CE; Wiese M
    Bioorg Med Chem; 2011 Mar; 19(6):2090-102. PubMed ID: 21354800
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cyclosporin A, tacrolimus and sirolimus are potent inhibitors of the human breast cancer resistance protein (ABCG2) and reverse resistance to mitoxantrone and topotecan.
    Gupta A; Dai Y; Vethanayagam RR; Hebert MF; Thummel KE; Unadkat JD; Ross DD; Mao Q
    Cancer Chemother Pharmacol; 2006 Sep; 58(3):374-83. PubMed ID: 16404634
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ixabepilone, a novel microtubule-targeting agent for breast cancer, is a substrate for P-glycoprotein (P-gp/MDR1/ABCB1) but not breast cancer resistance protein (BCRP/ABCG2).
    Shen H; Lee FY; Gan J
    J Pharmacol Exp Ther; 2011 May; 337(2):423-32. PubMed ID: 21262849
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ingredients in fruit juices interact with dasatinib through inhibition of BCRP: a new mechanism of beverage-drug interaction.
    Fleisher B; Unum J; Shao J; An G
    J Pharm Sci; 2015 Jan; 104(1):266-75. PubMed ID: 25418056
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The multidrug transporter ABCG2 (BCRP) is inhibited by plant-derived cannabinoids.
    Holland ML; Lau DT; Allen JD; Arnold JC
    Br J Pharmacol; 2007 Nov; 152(5):815-24. PubMed ID: 17906686
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phenolic indeno[1,2-b]indoles as ABCG2-selective potent and non-toxic inhibitors stimulating basal ATPase activity.
    Gozzi GJ; Bouaziz Z; Winter E; Daflon-Yunes N; Honorat M; Guragossian N; Marminon C; Valdameri G; Bollacke A; Guillon J; Pinaud N; Marchivie M; Cadena SM; Jose J; Le Borgne M; Di Pietro A
    Drug Des Devel Ther; 2015; 9():3481-95. PubMed ID: 26170632
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Kinetic analysis of the cooperation of P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp/Abcg2) in limiting the brain and testis penetration of erlotinib, flavopiridol, and mitoxantrone.
    Kodaira H; Kusuhara H; Ushiki J; Fuse E; Sugiyama Y
    J Pharmacol Exp Ther; 2010 Jun; 333(3):788-96. PubMed ID: 20304939
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance.
    Shi Z; Peng XX; Kim IW; Shukla S; Si QS; Robey RW; Bates SE; Shen T; Ashby CR; Fu LW; Ambudkar SV; Chen ZS
    Cancer Res; 2007 Nov; 67(22):11012-20. PubMed ID: 18006847
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Structure activity relationships and quantitative structure activity relationships for the flavonoid-mediated inhibition of breast cancer resistance protein.
    Zhang S; Yang X; Coburn RA; Morris ME
    Biochem Pharmacol; 2005 Aug; 70(4):627-39. PubMed ID: 15979586
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Metabolites of ginsenosides as novel BCRP inhibitors.
    Jin J; Shahi S; Kang HK; van Veen HW; Fan TP
    Biochem Biophys Res Commun; 2006 Jul; 345(4):1308-14. PubMed ID: 16729968
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of Walker A mutation (K86M) on oligomerization and surface targeting of the multidrug resistance transporter ABCG2.
    Henriksen U; Gether U; Litman T
    J Cell Sci; 2005 Apr; 118(Pt 7):1417-26. PubMed ID: 15769853
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of breast cancer resistance protein in acute lymphoblastic leukemia.
    Plasschaert SL; van der Kolk DM; de Bont ES; Kamps WA; Morisaki K; Bates SE; Scheffer GL; Scheper RJ; Vellenga E; de Vries EG
    Clin Cancer Res; 2003 Nov; 9(14):5171-7. PubMed ID: 14613996
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.